阿利西尤单抗用于近期急性冠脉综合征合并多血管病变患者:ODYSSEY OUTCOMES 试验
该研究为 ODYSSEY OUTCOMES 试验的预设分析,纳入近期急性冠脉综合征且经强化他汀治疗后仍存在血脂异常的患者,随机接受阿利西尤单抗或安慰剂。中位随访 2.8 年,结果显示多血管病变患者主要不良心血管事件和死亡风险高,阿利西尤单抗可带来大幅绝对风险降低。
要点
- 多血管病变患者 MACE 和死亡风险显著高于单血管病变者
- 阿利西尤单抗在 3 床多血管病变患者中 MACE 绝对风险降低 13.0%
- 阿利西尤单抗在 3 床多血管病变患者中死亡绝对风险降低 16.2%
核心结论
- 在近期 ACS 且经强化他汀治疗后仍存在血脂异常的患者中,多血管病变与高 MACE 和死亡风险相关。
- 阿利西尤单抗在这类患者中可带来大幅绝对风险降低,可能具有潜在获益。
研究设计与样本
- ODYSSEY OUTCOMES 试验的预设分析,患者随机接受阿利西尤单抗或安慰剂。
- 共纳入 18,924 例患者,中位随访 2.8 年。
主要发现
- 安慰剂组中,单血管病变、2 床多血管病变和 3 床多血管病变的 MACE 发生率分别为 10.0%、22.2% 和 39.7%。
- 阿利西尤单抗组对应的 MACE 绝对风险降低分别为 1.4%(95%CI 0.6%–2.3%)、1.9%(95%CI -2.4%–6.2%)和 13.0%(95%CI -2.0%–28.0%)。
- 安慰剂组中,上述三类患者的死亡发生率分别为 3.5%、10.0% 和 21.8%。
- 阿利西尤单抗组对应的死亡绝对风险降低分别为 0.4%(95%CI -0.1%–1.0%)、1.3%(95%CI -1.8%–4.3%)和 16.2%(95%CI 5.5%–26.8%)。
临床怎么用
- 对于近期 ACS 合并多血管病变且经强化他汀治疗后血脂仍不达标的患者,可考虑加用阿利西尤单抗以降低 MACE 和死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with acute coronary syndrome (ACS) and concomitant noncoronary atherosclerosis have a high risk of major adverse cardiovascular events (MACEs) and death. The impact of lipid lowering by proprotein convertase subtilisin-kexin type 9 inhibition in such patients is undetermined. OBJECTIVES: This pre-specified analysis from ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) determined whether polyvascular disease influenced risks of MACEs and death and their modification by alirocumab in patients with recent ACS and dyslipidemia despite intensive statin therapy. METHODS: Patients were randomized to alirocumab or placebo 1 to 12 months after ACS. The primary MACEs endpoint was the composite of coronary heart disease death, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. All-cause death was a secondary endpoint. RESULTS: Median follow-up was 2.8 years. Of 18,924 patients, 17,370 had monovascular (coronary) disease, 1,405 had polyvascular disease in 2 beds (coronary and peripheral artery or cerebrovascular), and 149 had polyvascular disease in 3 beds (coronary, peripheral artery, cerebrovascular). With placebo, the incidence of MACEs by respective vascular categories was 10.0%, 22.2%, and 39.7%. With alirocumab, the corresponding absolute risk reduction was 1.4% (95% confidence interval [CI]: 0.6% to 2.3%), 1.9% (95% CI: -2.4% to 6.2%), and 13.0% (95% CI: -2.0% to 28.0%). With placebo, the incidence of death by respective vascular categories was 3.5%, 10.0%, and 21.8%; the absolute risk reduction with alirocumab was 0.4% (95% CI: -0.1% to 1.0%), 1.3% (95% CI: -1.8% to 4.3%), and 16.2% (95% CI: 5.5% to 26.8%). CONCLUSIONS: In patients with recent ACS and dyslipidemia despite intensive statin therapy, polyvascular disease is associated with high risks of MACEs and death. The large absolute reductions in those risks with alirocumab are a potential benefit for these patients. (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab [ODYSSEY OUTCOMES]: NCT01663402).
引用
- Jukema JW, Szarek M, Zijlstra LE, et al. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial. J Am Coll Cardiol. 2019. PMID: 30898609. doi:10.1016/j.jacc.2019.03.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。